RxDoctor Payments Data

Richard Imsais, MD

Family Medicine · New Orleans, LANPI 1316188378

Payments from drug & device makers

$573in general payments, 2019–2025

Across 17 payments — averaging $33.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$279
  • Merck$94
  • Lilly USA, LLC$88
  • Dexcom, Inc.$69
  • Abbott$14
  • Exact Sciences$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk10$279
Merck1$94
Lilly USA, LLC1$88
Dexcom, Inc.2$69
Abbott1$14
Exact Sciences1$14
GSK1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$573 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$34,489
Medicare patients
159
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$118,871
OzempicSemaglutide66$95,802
JanuviaSitagliptin Phosphate56$66,189
TrulicityDulaglutide18$46,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$43,592
EliquisApixaban51$41,468
MounjaroTirzepatide28$33,650
FarxigaDapagliflozin Propanediol30$19,506
Breo ElliptaFluticasone/Vilanterol29$16,055
SymbicortBudesonide/Formoterol Fumarate13$4,647
Atorvastatin Calcium557$4,401
Albuterol Sulfate HfaAlbuterol Sulfate108$4,353
SynthroidLevothyroxine Sodium45$3,998
Losartan Potassium467$3,588
Levothyroxine Sodium505$3,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$279$95,80266 claims
Lilly USA, LLCTrulicity, Mounjaro$88$80,06946 claims
MerckJanuvia$94$66,18956 claims
GSKTrelegy Ellipta, Breo Ellipta$14$59,64773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →